Use of miRNA to Predict Therapy Response and Acute Toxicity to Radiotherapy in Patients with Prostate Cancer: Clinical Implementation of miRNA for Personalised Therapy

The study investigates whether analysis of blood and urine samples can better predict the course of disease and response to treatment in patients with prostate cancer.

Prostate cancer is one of the most common cancers in men. Although treatment is often successful, patients differ in their response to treatment and in the occurrence of adverse effects. In this study, we aim to determine whether specific molecular markers, called miRNAs, can help predict how an individual patient will respond to radiotherapy and what the risk of disease recurrence is.

Purpose of the study

To identify biological markers that enable prediction of response to radiotherapy, risk of treatment-related adverse effects, patient follow-up after treatment and early detection of disease recurrence.

Study procedure

This is a prospective and non-interventional study, meaning that patients receive standard treatment according to current guidelines.

If the patient decides to participate, they will provide additional blood and urine samples during regular visits. These samples will be used for molecular analyses. Follow-up will continue for several years after treatment, as part of regular follow-up visits.

At certain visits, patients will also complete questionnaires on quality of life and possible treatment-related problems.

The study does not affect the choice of treatment and does not involve any additional therapeutic procedures.

Who can take part?

Adult patients with prostate cancer who are referred for radiotherapy and meet the inclusion criteria.

How does inclusion take place?

The patient will be informed about the possibility of participation by a physician before the start of treatment. Before inclusion, the patient receives all necessary information and signs an informed consent form.

Participation is voluntary and may be withdrawn at any time without affecting further treatment.

The study involves only a minor additional burden, such as providing samples and completing questionnaires, and does not pose a significant additional risk to the patient.

Significance of the study

The results of the study may contribute to more personalised treatment of patients with prostate cancer and to more accurate disease monitoring and assessment of quality of life.